[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depressed\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depressed":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100617382","sensitivity-to-ovarian-hormones-and-depression-in-adolescents-100617382",false,"NCT07317895","Sensitivity to Ovarian Hormones and Depression in Adolescents","SOHDA","Inclusion Criteria:\n\n* Assigned female at birth, at least 1 year post-menarche, naturally cycling, history of depression or symptoms of depression, and able to read and write in English.\n\nExclusion Criteria:\n\n* Pregnant or taking any hormonal or cycle altering medications\u002Fdevices.","FEMALE","12 Years","18 Years",{"count":20,"type":21},94,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the relationship between changes in ovarian hormones (estrogen and progesterone) and adolescent depression. The main question it aims to answer is:\n\nCan we identify a subset adolescents assigned female at birth with a history of depression who are particularly sensitive to changes in ovarian hormones? Participants will be monitoring daily absolute ovarian hormone levels at home using the Mira Analyzer and answer online survey questions about their mental health for 90 days.",[25],"Depressed",[27,28,29],"Depression","Estrogen","Progesterone","NOT_YET_RECRUITING","2025-12-19",{"date":33,"type":34},"2026-01-05","ACTUAL",{"date":36,"type":21},"2026-03-01",{"date":38,"type":21},"2027-08-31",{"name":40,"class":41},"University of Calgary","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":42},"100609240","evaluation-of-dalia-solution-for-depressed-patient-100609240","NCT07211984","Evaluation of Dalia Solution For Depressed Patient","Evaluation of the Clinical and Organizational Impact of the Digital Medical Device Dalia in the Management of Depression","DaliaMonitorin","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient with a diagnosis of depressive episode, as defined by ICD-11, and with a PHQ-9 score ≥ 15 confirmed by a psychiatrist or general practitioner\n* Patient receiving a first antidepressant treatment (treatment-naïve) OR having had a modification of antidepressant treatment in the two weeks prior to inclusion\n* Patient equipped with a smartphone or a computer or a tablet with internet access\n* Patient affiliated to a health insurance scheme\n* Patient able to read and understand French\n* Patient having signed informed consent\n\nExclusion Criteria:\n\n* Patient under non-cardioselective beta-blocker (carvedilol, labetalol, propranolol, pindolol) and beta-mimetic (salbutamol, terbutaline)\n* Patient with a pacemaker or with a known cardiac arrhythmia\n* Patient with major neurocognitive disorder (e.g., dementia) or psychotic disorders likely to compromise participation in the study\n* Patient hospitalized at the time of inclusion whose discharge is not planned within the next two weeks\n* Patient treated with esketamine\n* Patient with excessive consumption of psychoactive substances (alcohol or drugs), which may interfere with the course or follow-up of the study\n* Patient unable to wear the bracelet during the study due to dermatological conditions\n* Patient under guardianship, curatorship, or legal protection, or any other administrative or judicial measure depriving rights and freedom\n* Patient considered non-autonomous by the investigator\n* Patient already included in another interventional research study\n* Vulnerable persons referred to in Articles L.1121-5 to 8 and L.1122-1-2 of the French Public Health Code are excluded from the study","ALL","76 Years",{"count":54,"type":21},644,"INTERVENTIONAL",[57],"NA","The goal of this superiority clinical investigation, prospective, multicenter, controlled, randomized, open-label is to evaluate the clinical impact of the Dalia medical telemonitoring device on the management of depressive patients. The main question it aims to answer is: the percentage of patients with clinically significant improvement at 3 months. A clinically significant improvement is defined as a decrease of at least 5 points from the initial PHQ-9 score AND\u002FOR a PHQ-9 score lower than 15. The threshold of 5 points is the Minimal Clinically Important Difference (MCID) of the PHQ-9 scale",[60,25,61,62,63],"Depression Chronic","Depressed Mood","Depression and Quality of Life","Depression Diagnosis",[27,65,66,67,68,69,70],"PHQ-9","MADRS","Depressive episode","Anxiety disorder","Antidepressant prescriptions","Smartwatch","2025-10-01",{"date":73,"type":34},"2025-10-08",{"date":75,"type":21},"2025-10-10",{"date":77,"type":21},"2026-03-31",{"name":79,"class":80},"Dalia Care","INDUSTRY"]